P
Patrick M. Wieruszewski
Researcher at Mayo Clinic
Publications - 81
Citations - 687
Patrick M. Wieruszewski is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 47 publications receiving 423 citations. Previous affiliations of Patrick M. Wieruszewski include University of Rochester & University of Florida.
Papers
More filters
Journal ArticleDOI
Improved Performance of Molecular Bulk‐Heterojunction Photovoltaic Cells through Predictable Selection of Solvent Additives
Kenneth R. Graham,Patrick M. Wieruszewski,Romain Stalder,Michael J. Hartel,Jianguo Mei,Franky So,John R. Reynolds,John R. Reynolds +7 more
TL;DR: In this article, a family of solvent additives spanning a wide range of Hansen solubility parameters is applied to a molecular bulk-heterojunction system consisting of an isoindigo and thiophene containing oligomer as the electron donor and [6,6]-phenyl-C61-butyric acid methyl ester (PC61BM) as the acceptor.
Journal ArticleDOI
Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers.
TL;DR: Current evidence suggests a role of biomarkers for the assessment of severity, and distinguishing sub-phenotypes (hyper-inflammatory versus hypo-inflammatory) with important prognostic and therapeutic implications in adjunct anti-inflammatory treatment with corticosteroids.
Journal ArticleDOI
Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome.
Patrick M. Wieruszewski,Jason N. Barreto,Erin Frazee,Craig E. Daniels,Pritish K. Tosh,Ross A. Dierkhising,Kristin C. Mara,Andrew H. Limper +7 more
TL;DR: The addition of early corticosteroids to anti‐Pneumocystis therapy in patients without HIV was not associated with improved respiratory outcomes.
Journal ArticleDOI
Tailor-made additives for morphology control in molecular bulk-heterojunction photovoltaics.
Kenneth R. Graham,Romain Stalder,Patrick M. Wieruszewski,Dinesh G. Patel,Danielle H. Salazar,John R. Reynolds,John R. Reynolds +6 more
TL;DR: Through the use of an asymmetric oligomer substituted with a bulky triisobutylsilyl end group, the morphology of BHJ blends can be controlled resulting in a near doubling (from 1.3 to 2.2%) in power conversion efficiency.
Journal ArticleDOI
Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation.
TL;DR: Increasing evidence supports DTIs use as safe and effective in extracorporeal membrane oxygenation patients with and without heparin-induced thrombocytopenia, and this review outlines the pharmacology, dosing strategies and available protocols, monitoring parameters, and special use considerations for all available DTIs.